Concerto Biosciences leverages its unmatched understanding of microbial ecology to discover breakthrough microbe-based therapeutics. The microbiome has been hailed as a promising target for the safe treatment of intractable diseases. However, reliably designing microbe-based therapeutics has remained elusive because no one understands the ecological mechanisms that underpin health-promoting microbiome functions. Concerto unlocks this knowledge with kChip—a platform that physically constructs and evaluates millions of miniature, defined microbial cocultures—and machine learning models of microbial ecology uniquely enabled by massive kChip datasets. Concerto’s lead asset, Ensemble No.2 (ENS-002), is a clinical-stage, topical, multi-strain live biotherapeutic product (LBP) for atopic dermatitis. Our discovery-stage asset, ENS-003, is an intravaginal LBP for recurrent vulvovaginal candidiasis. Through partnerships, we aim to commercialize these assets and launch new discovery initiatives.